SYNERGY: How Artificial Hormones Support Weight Loss

A new generation of drugs may become a "gamechanger" in the treatment of obesity and type 2 diabetes. In the recently published issue of the DZG magazine SYNERGIE, we present how different hormones are combined in polyagonists and how these new drugs contribute to weight loss.

When three components are combined, it is called a triple agonist. © SYNERGY / DZG

A breakthrough development in the fight against obesity and type 2 diabetes could improve the lives of millions of people. A new generation of drugs, polyagonists, has the potential to dramatically reduce body weight and increase feelings of satiety. These artificial hormones imitate the action of natural gut hormones and interfere with metabolic processes in the brain, leading to impressive results.

With the new type of medication, weight reductions similar to those achieved with surgical stomach reduction can be achieved: The polyagonists bind increasingly to the receptors for GLP-1 and GIP in the brain and enhance the feeling of satiety. The results are so convincing that this year the first representative of this new substance class was approved in the USA and Europe for the treatment of type 2 diabetes.

Read more in the current issue of the DZG magazine SYNERGIE (in German):
Künstliche Hormone erleichtern das Abnehmen | SYNERGIE (

You can find the entire issue here (in German):
SYNERGIE – Das Magazin der DZG (

The magazine can be subscribed to free of charge.
Abonnement | SYNERGIE (


Further information in our news from October 23, 2023: SYNERGIE: Blood Reflects Health and Diseases 


The German Centers for Health Research (DZG)
The goal of the German Centers for Health Research is translational research: the accelerated development of medical innovations. On the initiative of the German Federal Ministry of Education and Research, six centers were founded between 2009 and 2011 to better understand the causes of widespread diseases and to transfer research results from the laboratory to practice more quickly. The centers are dedicated to the following diseases: Cancer (DKTK), neurodegenerative diseases (DZNE), infectious diseases (DZIF), diabetes (DZD), lung diseases (DZL) and cardiovascular diseases (DZHK).
To this end, a total of 36 medical faculties and university hospitals work together with around 90 non-university institutes of the Helmholtz Association, the Leibniz Association, the Max Planck Society, the Fraunhofer Society and departmental research institutes of the federal government. Furthermore, there are collaborations with scientists in Germany and internationally.